UniProt ID | SMAD4_HUMAN | |
---|---|---|
UniProt AC | Q13485 | |
Protein Name | Mothers against decapentaplegic homolog 4 | |
Gene Name | SMAD4 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 552 | |
Subcellular Localization | Cytoplasm . Nucleus . Cytoplasmic in the absence of ligand. Migrates to the nucleus when complexed with R-SMAD (PubMed:15799969). PDPK1 prevents its nuclear translocation in response to TGF-beta (PubMed:17327236). | |
Protein Description | In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions (By similarity). Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for synergistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.. | |
Protein Sequence | MDNMSITNTPTSNDACLSIVHSLMCHRQGGESETFAKRAIESLVKKLKEKKDELDSLITAITTNGAHPSKCVTIQRTLDGRLQVAGRKGFPHVIYARLWRWPDLHKNELKHVKYCQYAFDLKCDSVCVNPYHYERVVSPGIDLSGLTLQSNAPSSMMVKDEYVHDFEGQPSLSTEGHSIQTIQHPPSNRASTETYSTPALLAPSESNATSTANFPNIPVASTSQPASILGGSHSEGLLQIASGPQPGQQQNGFTGQPATYHHNSTTTWTGSRTAPYTPNLPHHQNGHLQHHPPMPPHPGHYWPVHNELAFQPPISNHPAPEYWCSIAYFEMDVQVGETFKVPSSCPIVTVDGYVDPSGGDRFCLGQLSNVHRTEAIERARLHIGKGVQLECKGEGDVWVRCLSDHAVFVQSYYLDREAGRAPGDAVHKIYPSAYIKVFDLRQCHRQMQQQAATAQAAAAAQAAAVAGNIPGPGSVGGIAPAISLSAAAGIGVDDLRRLCILRMSFVKGWGPDYPRQSIKETPCWIEIHLHRALQLLDEVLHTMPIADPQPLD | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
7 | Phosphorylation | -MDNMSITNTPTSND -CCCCCCCCCCCCHH | 26.23 | 24719451 | |
9 | Phosphorylation | DNMSITNTPTSNDAC CCCCCCCCCCCHHHH | 21.20 | 25159151 | |
22 | Phosphorylation | ACLSIVHSLMCHRQG HHHHHHHHHHHHCCC | 13.60 | - | |
32 | Phosphorylation | CHRQGGESETFAKRA HHCCCCCCHHHHHHH | 45.25 | - | |
37 | Acetylation | GESETFAKRAIESLV CCCHHHHHHHHHHHH | 37.87 | 19608861 | |
42 | Phosphorylation | FAKRAIESLVKKLKE HHHHHHHHHHHHHHH | 32.14 | 26546556 | |
45 | Ubiquitination | RAIESLVKKLKEKKD HHHHHHHHHHHHCHH | 58.65 | 19608861 | |
45 | Malonylation | RAIESLVKKLKEKKD HHHHHHHHHHHHCHH | 58.65 | 26320211 | |
45 | Acetylation | RAIESLVKKLKEKKD HHHHHHHHHHHHCHH | 58.65 | 23749302 | |
48 | Acetylation | ESLVKKLKEKKDELD HHHHHHHHHCHHHHH | 76.11 | 155683 | |
59 | O-linked_Glycosylation | DELDSLITAITTNGA HHHHHHHHHHHCCCC | 19.80 | 33199824 | |
62 | O-linked_Glycosylation | DSLITAITTNGAHPS HHHHHHHHCCCCCHH | 16.25 | 33199824 | |
63 | O-linked_Glycosylation | SLITAITTNGAHPSK HHHHHHHCCCCCHHH | 26.07 | 33199824 | |
69 | O-linked_Glycosylation | TTNGAHPSKCVTIQR HCCCCCHHHCEEEEE | 28.90 | 33199824 | |
70 | Ubiquitination | TNGAHPSKCVTIQRT CCCCCHHHCEEEEEE | 36.86 | - | |
77 | Phosphorylation | KCVTIQRTLDGRLQV HCEEEEEECCCCEEE | 16.90 | 20974850 | |
88 | Malonylation | RLQVAGRKGFPHVIY CEEECCCCCCCHHHH | 65.08 | 26320211 | |
95 | Phosphorylation | KGFPHVIYARLWRWP CCCCHHHHEECCCCC | 5.65 | 27642862 | |
106 | Acetylation | WRWPDLHKNELKHVK CCCCCCCHHHCCCCC | 60.46 | 19608861 | |
113 | Sumoylation | KNELKHVKYCQYAFD HHHCCCCCCCCCCCC | 39.77 | - | |
113 | Ubiquitination | KNELKHVKYCQYAFD HHHCCCCCCCCCCCC | 39.77 | 21890473 | |
113 | Sumoylation | KNELKHVKYCQYAFD HHHCCCCCCCCCCCC | 39.77 | 28112733 | |
122 | Ubiquitination | CQYAFDLKCDSVCVN CCCCCCCCCCEEEEC | 37.53 | - | |
138 | Phosphorylation | YHYERVVSPGIDLSG HHHEEECCCCCCCCC | 17.98 | 27050516 | |
144 | Phosphorylation | VSPGIDLSGLTLQSN CCCCCCCCCCEECCC | 28.19 | 29523821 | |
147 | Phosphorylation | GIDLSGLTLQSNAPS CCCCCCCEECCCCCC | 26.69 | 28555341 | |
155 | Phosphorylation | LQSNAPSSMMVKDEY ECCCCCCCCEECCCE | 15.16 | 28555341 | |
159 | Sumoylation | APSSMMVKDEYVHDF CCCCCEECCCEEECC | 27.26 | - | |
159 | Sumoylation | APSSMMVKDEYVHDF CCCCCEECCCEEECC | 27.26 | - | |
162 | Phosphorylation | SMMVKDEYVHDFEGQ CCEECCCEEECCCCC | 17.14 | 28796482 | |
171 | Phosphorylation | HDFEGQPSLSTEGHS ECCCCCCCCCCCCCC | 27.37 | 28555341 | |
178 | Phosphorylation | SLSTEGHSIQTIQHP CCCCCCCCEEEEECC | 27.52 | 28555341 | |
206 | O-linked_Glycosylation | ALLAPSESNATSTAN CCCCCCCCCCCCCCC | 35.78 | 33199824 | |
209 | O-linked_Glycosylation | APSESNATSTANFPN CCCCCCCCCCCCCCC | 30.75 | 33199824 | |
211 | O-linked_Glycosylation | SESNATSTANFPNIP CCCCCCCCCCCCCCC | 22.67 | 33199824 | |
221 | O-linked_Glycosylation | FPNIPVASTSQPASI CCCCCCCCCCCCCHH | 28.91 | 33199824 | |
223 | O-linked_Glycosylation | NIPVASTSQPASILG CCCCCCCCCCCHHHC | 31.50 | 33199824 | |
265 | Phosphorylation | ATYHHNSTTTWTGSR CEECCCCCCEEECCC | 33.30 | - | |
269 | Phosphorylation | HNSTTTWTGSRTAPY CCCCCEEECCCCCCC | 24.16 | - | |
273 | Phosphorylation | TTWTGSRTAPYTPNL CEEECCCCCCCCCCC | 33.41 | - | |
277 | Phosphorylation | GSRTAPYTPNLPHHQ CCCCCCCCCCCCCCC | 12.49 | 12801888 | |
343 | Phosphorylation | GETFKVPSSCPIVTV CCEEECCCCCCEEEE | 47.78 | 22817900 | |
385 | Ubiquitination | RARLHIGKGVQLECK HHHCCCCCCCEEEEC | 56.13 | - | |
428 | Acetylation | APGDAVHKIYPSAYI CCCCHHHHHCCHHEE | 37.02 | 19608861 | |
428 | Malonylation | APGDAVHKIYPSAYI CCCCHHHHHCCHHEE | 37.02 | 26320211 | |
430 | Phosphorylation | GDAVHKIYPSAYIKV CCHHHHHCCHHEEEE | 8.92 | 28152594 | |
432 | Phosphorylation | AVHKIYPSAYIKVFD HHHHHCCHHEEEEEE | 19.41 | 28152594 | |
434 | Phosphorylation | HKIYPSAYIKVFDLR HHHCCHHEEEEEEHH | 12.95 | 28152594 | |
504 | Phosphorylation | RLCILRMSFVKGWGP HHHHHHHHHHCCCCC | 22.06 | 24719451 | |
507 | Ubiquitination | ILRMSFVKGWGPDYP HHHHHHHCCCCCCCC | 47.11 | 19608861 | |
507 | Acetylation | ILRMSFVKGWGPDYP HHHHHHHCCCCCCCC | 47.11 | 19608861 | |
507 | Malonylation | ILRMSFVKGWGPDYP HHHHHHHCCCCCCCC | 47.11 | 26320211 | |
513 | Phosphorylation | VKGWGPDYPRQSIKE HCCCCCCCCCCCCCC | 11.93 | 24719451 | |
519 | Ubiquitination | DYPRQSIKETPCWIE CCCCCCCCCCCCEEE | 61.86 | 21890473 | |
543 | Sulfoxidation | LDEVLHTMPIADPQP HHHHHHHCCCCCCCC | 1.25 | 30846556 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
9 | T | Phosphorylation | Kinase | NLK | Q9UBE8 | PSP |
77 | T | Phosphorylation | Kinase | STK11 | Q15831 | GPS |
138 | S | Phosphorylation | Kinase | NLK | Q9UBE8 | PSP |
265 | T | Phosphorylation | Kinase | GSK3B | P49841 | PSP |
269 | T | Phosphorylation | Kinase | GSK3B | P49841 | PSP |
273 | T | Phosphorylation | Kinase | GSK3B | P49841 | PSP |
277 | T | Phosphorylation | Kinase | MAPK3 | P27361 | GPS |
343 | S | Phosphorylation | Kinase | MELK | Q61846 | PSP |
- | K | Ubiquitination | E3 ubiquitin ligase | TRIM33 | Q9UPN9 | PMID:15820681 |
- | K | Ubiquitination | E3 ubiquitin ligase | SMURF2 | Q9HAU4 | PMID:15817471 |
- | K | Ubiquitination | E3 ubiquitin ligase | BTRC | Q9Y297 | PMID:14988407 |
- | K | Ubiquitination | E3 ubiquitin ligase | SKP2 | Q13309 | PMID:15314162 |
- | K | Ubiquitination | E3 ubiquitin ligase | STUB1 | Q9UNE7 | PMID:14701756 |
- | K | Ubiquitination | E3 ubiquitin ligase | WWP1 | Q9H0M0 | PMID:15817471 |
Modified Location | Modified Residue | Modification | Function | Reference |
---|---|---|---|---|
519 | K | ubiquitylation |
| 19135894 |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of SMAD4_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
260350 | Pancreatic cancer (PNCA) | |||||
174900 | Juvenile polyposis syndrome (JPS) | |||||
175050 | Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome (JP/HHT) | |||||
187300] in a single individual. JIP and HHT are autosomal dominant disorders with distinct and non-overlapping clinical features. The former, an inherited gastrointestinal malignancy predisposition, is caused by mutations in SMAD4 or BMPR1A, and the latter is a vascular malformation disorder caused by mutations in ENG or ACVRL1. All four genes encode proteins involved in the transforming-growth-factor-signaling pathway. Although there are reports of patients and families with phenotypes of both disorders combined, the genetic etiology of this association is unknown. {ECO | ||||||
Colorectal cancer (CRC) [ | DISEASE | |||||
Note=SMAD4 variants may be associated with susceptibility to pulmonary hypertension, a disorder characterized by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right ventricular failure, and death. The disease can occur from infancy throughout life and it has a mean age at onset of 36 years. Penetrance is reduced. Although familial pulmonary hypertension is rare, cases secondary to known etiologies are more common and include those associated with the appetite-suppressant drugs. | ||||||
139210 | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-37; LYS-428 AND LYS-507, ANDMASS SPECTROMETRY. |